Goldman Sachs is out with a research report on Pfizer PFE and is adding the stock to its Conviction Buy list and it has a $22 price target.
In a note to clients, Goldman Sachs writes, "We are adding PFE to the Conviction List, as we view PFE as a dislocated Buy opportunity in US Major Pharma, given (1) its dynamic management team that has shown commitment to delivering value to shareholders through announced spin-offs/divestitures and dividends/share buybacks, (2) significant 2H2011 pipeline catalysts that could change investor sentiment, (3) management's focus on fixing the R&D engine could drive significant long-term value if successful, and (4) significant and building cash balances that affords tremendous flexibility. We see 32% upside to our 12-month price target of $22."
Shares of PFE lost 83 cents yesterday to close at $16.66 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in